Developer of a fresh therapeutic course of biologics called Adnectins.

Furthermore, Adnexus exclusively controls its patented PROfusion proteins design engine. Adnexus has more than 100 issued and pending patent properties relating to Adnectins and PROfusion.. Adnexus Therapeutics to become subsidiary of Bristol-Myers Squibb Bristol-Myers Squibb and Adnexus Therapeutics possess announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a fresh therapeutic course of biologics called Adnectins.Genome sequencing of bacterias has revealed that these active gene clusters are outnumbered approximately ten times by so-known as silent gene clusters. Related StoriesCHOP experts delay symptoms, lengthen lifespan in animal style of Batten diseaseApoE4-carrying men with Alzheimer's disease vulnerable to human brain bleedsResearchers identify tumor suppressor genes that drive subset of melanomas Turning these clusters on would really expand our available chemical space to find new antibiotic or elsewhere therapeutically useful molecules, Seyedsayamdost said. Within an article published last week in the journal Proceedings of the National Academy of Sciences, Seyedsayamdost reported a strategy to quickly screen entire libraries of substances to find elicitors, small molecules that may turn on a specific gene cluster.